InSightec has completed enrolling patients for its MRgFUS essential tremor feasibility trial.
The trial is designed to assess the safety and initial effectiveness of the use of MrgFUS using ExAblate Neuro.
InSightec explains that ExAblate Neuro combines high intensity focused ultrasound for deep accurate lesioning of the brain, with continuous realtime MR guidance for visualizing brain anatomy, planning and monitoring treatment and outcome.
InSightec Neuro programVP of R&D and director Eyal Zadicario said ExAblate Neuro has demonstrated the ability to ablate targets deep in the brain with high precision.
"Encouraging initial results provide hope that this treatment could become a significant addition for treating neurological disorders", Zadicario said.
"InSightec is expanding its Neuro research, to include brain tumors, stroke and targeted drug delivery."